Friday, 19 Jan 2018

You are here

It's Rheumatoid Arthritis, not the TNF inhibitor, that Drives Lymphoma Risk

Evidence from multiple studies suggests there is an increased risk of lymphoma in rheumatoid arthritis (RA) that is believed to be linked to the cumulative activity of the disease.  

It is also debated whether  biologic and non-biologic treatments increase this risk. Rheumatoid arthritis (RA) patients showed to have higher incidence of diffuse large B –cell lymphoma (DLBCL) unrelated to biologic therapy. There is very little data on lymphoma risk in non-TNF biologic treatment groups.

Possible association between use of methotrexate and EBV-positive lymphoproliferative disorders was reported; as well as increased risk of lymphoma in TNF-treated Crohns’ patients was reported prior.

A collaborative analysis of twelve European biologic registers from nine countries aimed to study if there might be a switch in the subtype distribution of lymphomas in RA linked to specific antirheumatic treatments.

Among close to 125,000 registry patients, 533 developed lymphomas. Multiple steps were taken to analyze the spectrum of lymphoma subtypes.

No significant differences in the distribution of Hodgkins lymphoma (HL) versus B-NHL versus T-NHL between patients who were either bionaïve or TNFi-treated..

After standardizing by age, the distribution of HL versus B-NHL versus T-NHL observed in the RA group was comparable to that seen in the  general population.

Within the B-NHL subtype, however, DLBCL was significantly higher in RA compared with the general population (56% of all B-NHL in RA vs 30% in the general population); whereas CLL was significantly less frequent (16% of all B-NHL in RA vs 38% in the general population).

Only six, six and three lymphomas occurred in patients treated with rituximab, tocilizumab and abatacept, respectively, at lymphoma diagnosis. As a result, authors were not able to analyze data in non-TNF group due to small sample size.

It has been pointed out that the comparison between the treatment groups might be affected by age difference, since the age is an important factor in lymphogenesys.

Authors could not analyze any potential influence of additional therapies with MTX or other conventional synthetic DMARDs.

In general, the analysis supported the conclusion that the risk of lymphoma in RA is more dependent on RA itself and especially the disease activity than on the RA treatment; the spectrum of lymphoma subtypes seems not to be altered by TNFi.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Why TNF Inhibitors May Work in Some Autoinflammatory Patients

The NLRP3 inflammasome is a critical component of the innate immune system and activation of NLRP3 inflammasome results in caspase-1–dependent secretion of the proinflammatory cytokines IL-1β and IL-18. Gain-of-function missense mutations in NLRP3 is thought to drive many of the autoinflammatory diseases, especially the cryopyrin-associated periodic syndromes (CAPS).

Infliximab Does Not Increase Perioperative Infection

Staying on a TNF inhibitor (TNFi) throughout major surgery has generatlly been associated with higher rates of perioperative infection (https://buff.ly/2iBFVjp).  On the other hand, discontinuation of the TNFi prior to surgery is associated with lower rates of  infection (https://buff.ly/2iAFZQf)

CALM Study: Tight Control with Anti-TNF Wins in Crohn's Disease

Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein. But Lancet has now reported a clinical trial has shown that a tight control strategy can yield better responses to TNF inhibitors when compared to usual care. 

Amgen-Abbvie Settle Humira Biosimilar Patent Dispute

Amgen's biosimilar version of adalimumab (Humira) was FDA-approved in September 2016 and given the trade name Amjevita (generic: adalimumab-atto). This new TNF inhibitor biosimilar has not yet been to market because of legal wranglings over patent issues by Abbvie's Humira.

Another Adalimumab Biosimilar Approved

On Friday August 25th, the FDA approved another adalimumab biosimilar: Cyltezo (generic name: adalimumab-adbm).